X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ALEMBIC PHARMA with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC PHARMA   ACTAVIS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
ACTAVIS
Dec-14
ALEMBIC PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs79217,421-   
Low Rs44310,626-   
Sales per share (Unadj.) Rs167.03,137.0-  
Earnings per share (Unadj.) Rs38.2-391.5-  
Cash flow per share (Unadj.) Rs42.0287.8-  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.96,804.1-  
Shares outstanding (eoy) m188.52265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.74.5 82.7%   
Avg P/E ratio x16.2-35.8 -45.2%  
P/CF ratio (eoy) x14.748.7 30.2%  
Price / Book Value ratio x7.32.1 352.8%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3833,728,890 3.1%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m4,2140-   
Avg. sales/employee Rs ThNM38,617.6-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-4,819.1-  
INCOME DATA
Net Sales Rs m31,487834,139 3.8%  
Other income Rs m55-2,082 -2.6%   
Total revenues Rs m31,542832,057 3.8%   
Gross profit Rs m10,060107,157 9.4%  
Depreciation Rs m722180,622 0.4%   
Interest Rs m3726,310 0.1%   
Profit before tax Rs m9,356-101,857 -9.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-7,472 0.0%   
Tax Rs m2,160-5,237 -41.3%   
Profit after tax Rs m7,194-104,092 -6.9%  
Gross profit margin %31.912.8 248.7%  
Effective tax rate %23.15.1 449.1%   
Net profit margin %22.8-12.5 -183.1%  
BALANCE SHEET DATA
Current assets Rs m15,066439,485 3.4%   
Current liabilities Rs m7,674320,513 2.4%   
Net working cap to sales %23.514.3 164.6%  
Current ratio x2.01.4 143.2%  
Inventory Days Days6758 115.4%  
Debtors Days Days4166 61.3%  
Net fixed assets Rs m8,237101,857 8.1%   
Share capital Rs m3770-   
"Free" reserves Rs m15,4160-   
Net worth Rs m16,0051,809,218 0.9%   
Long term debt Rs m0948,066 0.0%   
Total assets Rs m24,5943,315,701 0.7%  
Interest coverage x255.2-2.9 -8,889.1%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.30.3 508.9%   
Return on assets %29.4-2.3 -1,253.4%  
Return on equity %44.9-5.8 -781.3%  
Return on capital %58.7-3.0 -1,948.8%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Net fx Rs m12,4930-   
CASH FLOW
From Operations Rs m9,304143,238 6.5%  
From Investments Rs m-3,105-342,967 0.9%  
From Financial Activity Rs m-1,959192,698 -1.0%  
Net Cashflow Rs m4,240-7,031 -60.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.86 Rs / USD

Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ALEMBIC PHARMA With: ALEMBIC LTD  TTK HEALTHCARE  STRIDES SHASUN LTD  WYETH LTD  FRESENIUS KABI ONCO.  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 18, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS